Course of inflammation and infection markers differ in ICU patients with severe COVID-19 under casirivimab- and/or tocilizumab application: an observational study
Iustila-Maran et al., Research Square, doi:10.21203/rs.3.rs-4090027/v1
https://c19early.org/iustilamaran.html